ACC 2021 In patients undergoing coronary angiography in the INSPIRE registry, higher levels of EPA unadjusted and adjusted for DHA were associated with lower MACE and in contrast, higher DHA levels adjusted for EPA were associated with higher MACE.
ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.
ACC 2021 In patients who had used DAPT for 6-18 months after PCI with DES, clopidogrel monotherapy as chronic maintenance therapy for 2 years reduced ischemic and bleeding outcomes compared to aspirin monotherapy.
ACC 2021 Prof. Ridker talks about anti-inflammatory therapies to prevent CVD: What is the right drug and what is the right target population?
ACC 2021 The phase 2 RESCUE trial showed that the IL-6 inhibitor ziltivekimab largely reduced hsCRP and other biomarkers of inflammation and thrombosis in patients with CKD and ≥2 mg/L hsCRP.
ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.
ACC 2021 Results from the HOLIDAY study suggest that just one alcoholic drink was associated with a 2-fold greater odds and two or more alcoholic drinks were associated with a 3.5-fold greater odds of a discrete AF episode occurring in the next four hours.
ACC 2021 REHAB-HF showed that individualized physical rehabilitation intervention, compared to usual care, resulted in significant improvements in physical function, frailty status, quality of life, and depression in older patients with ADHF.
ACC 2021 In response to a new subanalysis of the STRENGTH trial, prof. Handberg discusses possible studies that can provide more insights to solve the controversy on omega-3FAs trials.
ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.
ACC 2021 In the ADAPTABLE trial, the efficacy and safety of 81 mg aspirin was compared to 325 mg aspirin. William Schuyler Jones tells us what these results mean for contemporary patients using 81 mg or 325 mg aspirin.
ACC 2021 A pooled patient-level analysis showed that sotagliflozin significantly reduced total CV deaths, HF hospitalizations, and urgent visits for HF across the full range of baseline EF, including in patients with HFpEF.